Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Current Assets (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of Current Assets data on record, last reported at $6.0 million in Q3 2025.

  • For Q3 2025, Current Assets rose 339.0% year-over-year to $6.0 million; the TTM value through Sep 2025 reached $6.0 million, up 339.0%, while the annual FY2024 figure was $1.1 million, 39.92% down from the prior year.
  • Current Assets reached $6.0 million in Q3 2025 per COEP's latest filing, up from $3.7 million in the prior quarter.
  • Across five years, Current Assets topped out at $6.0 million in Q3 2025 and bottomed at $30967.0 in Q3 2022.
  • Average Current Assets over 5 years is $2.0 million, with a median of $1.6 million recorded in 2023.
  • Peak YoY movement for Current Assets: tumbled 94.87% in 2022, then skyrocketed 5132.91% in 2023.
  • A 5-year view of Current Assets shows it stood at $2.2 million in 2021, then soared by 80.85% to $3.9 million in 2022, then crashed by 55.61% to $1.7 million in 2023, then crashed by 39.92% to $1.1 million in 2024, then surged by 469.86% to $6.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $6.0 million in Q3 2025, $3.7 million in Q2 2025, and $4.7 million in Q1 2025.